CVS vs ZYME · P/E 16, rev $402.07B vs rev $76.3M
CVS Health Corp (CVS) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
CVS currently screens at market cap $86.20B and trailing P/E 16.3. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the CVS and ZYME stock pages for the full models.
Not investment advice.